Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties
San Diego, CA – November 14, 2024 – Neurelis, Inc. (“Company”), today announced a transaction with OrbiMed for the sale of the Company’s rights, royalty interests, and related sales milestone payments on global net sales of neffy® (nasal epinephrine) (the “Neffy Receivables”). Neurelis, through its subsidiary Aegis Therapeutics, LLC (“Aegis”), previously entered into an agreement […]
NEURELIS TO SHARE CLINICAL STUDY DESIGN INSIGHTS FOR INVESTIGATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 AT CHILD NEUROLOGY SOCIETY ANNUAL MEETING
San Diego, CA – November 11, 2024 – Neurelis, Inc., today announced a presentation on insights into study design from the enrollment process for the new Stellina study investigating VALTOCO® (diazepam nasal spray) for the treatment of seizure clusters in patients with epilepsy aged 2 to 5 years. This age group is not included in […]
NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE 76TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
San Diego, CA – [April 11, 2024] – Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations. A second presentation will provide insight into […]
Neurelis Pipeline Update – Advancements to Address Unmet Needs in Neuroscience – Replay
Neurelis hosted an investor call to highlight updates on two of its neuroscience product development candidates, NRL-1004 for acute agitation episodes and NRL-1049 for cerebral cavernous malformations (CCMs). A replay can be found at the link here.
NEURELIS ANNOUNCES NEW ROLES FOR TOP EXECUTIVES TO ADVANCE CLINICAL AND STRATEGIC INITIATIVES AND POSITION FOR FUTURE GROWTH
Dr. Rabinowicz and Dr. Carrazana have been instrumental in synergistically advancing novel therapies to address unmet needs in the epilepsy and broader central nervous system (CNS) communities SAN DIEGO, CA — May 15, 2023 — Neurelis, Inc., announced today the promotion of Adrian L. Rabinowicz, MD, to Chief Medical Officer and the establishment of a […]
NEURELIS ANNOUNCES FOUR POSTER PRESENTATIONS AT THE 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
Quality of life and overall duration of seizures data with use of VALTOCO® (diazepam nasal spray) CIV to be presented at AAN SAN DIEGO, CA — April 25, 2023 — Neurelis, Inc. will present four posters from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity […]
NEURELIS ANNOUNCES FIRST HEALTHY SUBJECTS DOSED IN INVESTIGATIONAL STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS
First in human study will evaluate safety, tolerability, and pharmacokinetic parameters of NRL-1049, a Rho kinase (ROCK) inhibitor SAN DIEGO, CA — March 24, 2023 — Neurelis, Inc., announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential treatment for people living with cerebral cavernous […]
NEURELIS WINS 2023 PM360 PHARMA CHOICE MULTICHANNEL GOLD AWARD FOR ‘GIVE SEIZURES THE SPRAYER’ MARKETING CAMPAIGN
‘Give Seizures the Sprayer’, marketing campaign led by Beth Henriksen, Director of Marketing, Neurelis, Inc., wins the 2023 PM360 Pharma Choice Multichannel Gold Award SAN DIEGO, CA — March 2, 2023 — Neurelis, Inc. is proud to announce the ‘Give Seizures the Sprayer’ marketing campaign for VALTOCO® (diazepam nasal spray) CIV has won a 2023 […]
NEURELIS ANNOUNCES FILING OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS
Pre-clinical data recently presented at Society for Neuroscience’s annual meeting demonstrates NRL-1049 potential safety, Neurelis to advance further studies SAN DIEGO, CA — January 9, 2023 — Neurelis, Inc., announced the successful filing of its investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NRL-1049, a Rho kinase (ROCK) inhibitor with […]
NEURELIS CONGRATULATES INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS, FOR FDA ACCEPTANCE OF INTRANASAL EPINEPHRINE NDA
neffy® (epinephrine nasal spray), is developed with Neurelis’ proprietary Intravail® Absorption-Enhancing Technology SAN DIEGO, CA — December 8, 2022 — ARS Pharmaceuticals, Inc., announced that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application (NDA) for neffy (previously referred to as ARS-1), for the emergency treatment of severe type I allergic […]